Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK1 | P49759 | 1/20 | 0.51 |
| ▸ | DPP4 | P27487 | 1/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 3/20 | 0.49 |
| ▸ | ACHE | P22303 | 3/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.49 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.49 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 2/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | APP | P05067 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12733642 | 0.93 | CLK1 (0.51) | CLK1DPP4ADORA3KDM4EALDH1A1 | |
| SCHEMBL72801 | 0.80 | DCPS (0.64) | CLK1ADORA3KDM4EALDH1A1HPGD | |
| SCHEMBL29583288 | 0.80 | DCPS (0.64) | CLK1ADORA3KDM4EALDH1A1HPGD | |
| SCHEMBL5212065 | 0.79 | GPR3 (0.66) | KDM4EALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL30659937 | 0.79 | GPR3 (0.66) | KDM4EALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL72366 | 0.78 | ADORA3 (0.45) | ADORA3ALDH1A1ACHEADORA2AHTR3A | |
| SCHEMBL11057550 | 0.76 | ACHE (0.67) | ADORA3KDM4EALDH1A1HPGDACHE | |
| SCHEMBL7795994 | 0.76 | ACHE (0.67) | ADORA3KDM4EALDH1A1HPGDACHE | |
| SCHEMBL28091313 | 0.76 | MAOA (0.46) | KDM4EALDH1A1ACHEMEN1NPC1 | |
| SCHEMBL9709249 | 0.76 | MAOA (0.72) | ADORA3KDM4EALDH1A1HPGDACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122916-A1 | SCREENING MOLECULES WITH ANTI-PRION ACTIVITY: KITS, METHODS AND SCREENED MOLECULES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2012-05-17 | — | — | US | disclosed |
| US-8129402-B2 | Screening molecules with anti-prion activity: kits, methods and screened molecules | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2012-03-06 | — | — | US | disclosed |
| US-20110092483-A1 | SCREENING MOLECULES WITH ANTI-PRION ACTIVITY: KITS, METHODS AND SCREENED MOLECULES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2011-04-21 | — | — | US | disclosed |
| US-20070031821-A1 | Screening molecules with anti-prion activity: kits, methods and screened molecules | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS ) (FR) | 2007-02-08 | — | — | US | disclosed |
| EP-1551992-B1 | SCREENING MOLECULES WITH ANTI-PRION ACTIVITY: KITS, METHODS AND SCREENED MOLECULES | CENTRE NAT RECH SCIENT (FR) | 2006-12-27 | — | — | EP | disclosed |
| US-20060172337-A1 | Screening molecules with anti-prion activity: kits, methods and screened molecules | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2006-08-03 | — | — | US | disclosed |
| EP-1551992-A2 | SCREENING MOLECULES WITH ANTI-PRION ACTIVITY: KITS, METHODS AND SCREENED MOLECULES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2005-07-13 | — | — | EP | disclosed |
| WO-2004035813-A2 | SCREENING MOLECULES WITH ANTI-PRION ACTIVITY: KITS, METHODS AND SCREENED MOLECULES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2004-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122916-A1 | SCREENING MOLECULES WITH ANTI-PRION ACTIVITY: KITS, METHODS AND SCREENED MOLECULES | PRPF6, PRNP, TDP1 | CLK1 2169/4885DPP4 2377/4885ADORA3 985/4885 |
| US-20110092483-A1 | SCREENING MOLECULES WITH ANTI-PRION ACTIVITY: KITS, METHODS AND SCREENED MOLECULES | ATXN2L, ATXN10, CLN6 | CLK1 2185/4885DPP4 2897/4885ADORA3 1609/4885 |
| US-20070031821-A1 | Screening molecules with anti-prion activity: kits, methods and screened molecules | ATXN2L, ATXN10, CLN6 | CLK1 2185/4885DPP4 2897/4885ADORA3 1609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.